Financials
| Final Results | Nov. 11, 2025 |
| Trading update | Aug. 05, 2025 |
| Half-year Report | Mar. 24, 2025 |
| Final Results | Oct. 08, 2024 |
| Trading Update | Jul. 09, 2024 |
| Interim Results | Mar. 14, 2024 |
| Trading Update | Jan. 11, 2024 |
Proxies
| Result of Annual General Meeting | Dec. 10, 2025 |
| Notice of AGM & Publication of 2025 Annual Report | Nov. 14, 2025 |
| Result of AGM | Nov. 19, 2024 |
| AGM Statement | Nov. 19, 2024 |
| Notice of AGM | Oct. 21, 2024 |
| AGM Statement | Dec. 15, 2023 |
| Notice of Annual General Meeting | Nov. 22, 2023 |
Ownership Update
| Director/PDMR Shareholding | Aug. 14, 2025 |
| Award of Options under LTIP | May. 02, 2025 |
| TR-1 | Aug. 19, 2024 |
| TR-1 | Aug. 19, 2024 |
| TR-1 | Aug. 19, 2024 |
| Director/PDMR Shareholding | Oct. 25, 2023 |
| Award of Options under LTIP | Oct. 24, 2023 |
Announcements
| EMI Share Option Scheme | Apr. 15, 2026 |
| Trading to commence on the OTCQB in the US | Apr. 14, 2026 |
| £4.8m contracts awarded | Mar. 30, 2026 |
| Half-year Financial Report | Mar. 17, 2026 |
| $2.5m Contract for clinical self-test development | Mar. 12, 2026 |
| Trading on the OTCQB Venture Market in the US | Mar. 10, 2026 |
| Appointment of NOMAD & Corporate Broker | Jan. 15, 2026 |